Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist

European Journal of Pharmacology

Volumn 325, Issue 1, 1997, Pages 69-80

  Albert, Daniel H ^a   Magoc, Terrance J ^a   Tapang, Paul ^a   Luo, Gongjin ^a   Morgan, Douglas W ^a   Curtin, Michael ^a   Sheppard, George S ^a   Xu, Lianhong ^a   Heyman, H Robin ^a   Davidsen, Steven K ^a   Summers, James B ^a   Carter, George W ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

ABT 491; Ca2+ flux; Degranulation; Endotoxemia; PAF (platelet activating factor); PAF receptor antagonist; Superoxide anion; Vascular permeability

Indexed keywords

4 ETHYNYL 3 [3 FLUORO 4 [(2 METHYL 1H IMIDAZO[4,5 C]PYRIDIN 1 YL)METHYL]BENZOYL] N,N DIMETHYL 1H INDOLE 1 CARBOXAMIDE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CALCIUM MOBILIZATION; CONTROLLED STUDY; DIGESTIVE SYSTEM INJURY; DRUG RECEPTOR BINDING; EDEMA; GUINEA PIG; HUMAN; HUMAN CELL; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LETHALITY; MALE; MAST CELL DEGRANULATION; MOUSE; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; RAT; SPECIES DIFFERENCE; THROMBOCYTE;

ACUTE DISEASE; ANIMALS; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTOXEMIA; GUINEA PIGS; HUMANS; IMIDAZOLES; INDOLES; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED ICR; NEUTROPHILS; PLATELET ACTIVATING FACTOR; PLATELET MEMBRANE GLYCOPROTEINS; RABBITS; RATS; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; SHOCK;

EID: 0030963469     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)00109-X     Document Type: Article

References (50)

1. Albert, D.H., Conway, R.G., Magoc, T.J., Tapang, P., Rhein, D.A., Luo, G., Holms, J.H., Davidsen, S.K., Summers, J.B., Carter, G.W., 1996a. Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist. J. Pharmacol. Exp. Ther. 277, 1595-1606.
2. Albert, D.H., Luo, G., Magoc, T.J., Tapang, P., Holms, J.H., Davidsen, S.K., Summers, J.B., Carter, G.W., 1996b. ABT-299, a novel PAF antagonist, attenuates multiple effects of endotoxemia in conscious rats. Shock 6, 112-117.
3. Allen, R.C., 1986. Phagocytic leukocyte oxygenation activities and chemiluminescence: a kinetic approach to analysis. Methods Enzymol. 133, 449-493.
4. 4 in human neutrophils. Pharmacol. Res. Commun. 18, 51-59.
5. Bel, E.H., De Smet, M., Rossing, T.H., Timmers, M.C., Dijkman, J.H., Sterk, P.J., 1991. The effect of a specific oral PAF-antagonist, MK-287, on antigen-induced early and late asthmatic reactions in man. Am. Rev. Respir. Dis. 143, A811.
6. Bernat, A., Herbert, J.M., Salel, V., Lespy, L., Maffrand, J.P., 1992. Protective effect of SR 27417, a novel PAF antagonist, on PAF- or endotoxin-induced hypotension in the rat and the guinea-pig. J. Lipid Mediat. 51, 41-48.
7. Blank, M.L., Snyder, F., Byers, L.W., Brooks, B., Muirhead, 1979. Antihypertensive activity of an alkyl ether analog phosphatidyl choline. Biochem. Biophys. Res. Commun. 906, 1200.
8. Blank, M.L., Lee, T.C., Fitzgerald, V., Snyder, F., 1981. A specific hydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine hypotensive platelet activating lipid. J. Biol. Chem. 256, 175-178.
9. Braquet, P., Paubert-Braquet, M., Bessin, P., Vargaftig, B.B., 1987a. Platelet-activating factor: a potential mediator of shock. Adv. Prostaglandin Thromboxane Leukotriene Res. 7, 822-827.
10. Braquet, P., Touqui, L., Shen, T.Y., Vargaftig, B.B., 1987b. Perspectives in platelet-activating factor research. Pharmacol. Rev. 39, 97-145.
11. Braquet, P., Paubert-Braquet, M., Koltai, M., Bourgain, R., Bussolino, F., Hosford, D., 1989. Is there a case for PAF antagonists in the treatment of ischemic states? Trends Pharmacol. Sci. 10, 23-30.
12. Carlson, R.P., O'Neill-Davis, L., Chang, J., 1987. Pharmacologic modulation of PAF-induced mortality in mice. Agents Actions 21, 379-381.
13. Chang, S.W., Feddersen, C.O., Henson, P.M., Voelkel, N.F., 1987. Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J. Clin. Invest. 79, 1498-1509.
14. Curtin, M.L., Carrera, J.G.M., Florjancic, A.S., Garland, R.B., Heyman, H.R., Sheppard, G.S., Steinman, D.H., Trautmann, J.A., Xu, L., Davidsen, S.K., Conway, R.G., Rhein, D.A., Albert, D.H., Luo, G., Magoc, T.J., Tapang, P., Morgan, D.W., Summers, J.B., Carter, G.W., 1996. Discovery and Characterization of A-137491, A Potent Antagonist of Platelet Activating Factor. 211th ACS National Meeting, New Orleans, Louisiana, March, 1996.
15. Dermarkarian, R.M., Israel, E., Rosenberg, M.A., Jansen, A., Danzig, M.R., Fourre, J., Drazen, J.M., 1991. The effect of Sch-37370, a dual PAF and histamine antagonist, on the bronchoconstriction induced in asthmatics by cold, dry air isocapnic hyperventilation. Am. Rev. Respir. Dis. 143, A812.
16. Dewald, B., Baggiolini, M., 1987. Evaluation of PAF antagonists using human neutrophils in a microtiter plate assay. Biochem. Pharmacol. 36, 2505-2510.
17. Doebber, T.W., Wu, M.S., Robbins, J.C., Choy, B.M., Chang, M.N., Shen, T.Y., 1985. Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonist kadsurenone. Biochem. Biophys. Res. Commun. 127, 799-808.
18. Freitag, A., Watson, R.M., Matsos, G., Eastwood, C., O'Byrne, P.M., 1993. Effect of a PAF antagonist WEB-2086, on allergen induced asthmatic response. Thorax 48, 594-598.
19. Gay, J.C., 1993. Mechanism and regulation of neutrophil priming by platelet-activating factor. J. Cell Physiol. 156, 189-197.
20. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260, 3440-3445.
21. Herbert, J.M., Fraisse, L., Bachy, A., Valette, G., Savi, P., Laplace, M.C., Lassale, J., Roche, B., Lale, A., Keane, P.E., Maffrand, J.P., 1993a. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist. J. Lipid Mediat. 8, 31-51.
22. 3H]SR 27417, a novel platelet-activating factor (PAF) receptor antagonist, to rabbit and human platelets and polymorphonuclear leukocytes. Biochem. Pharmacol. 45, 51-58.
23. Honda, Z., Nakamura, M., Miki, I., Minami, M., Watanabe, T., Seyama, Y., Okado, H., Toh, H., Ito, K., Miyamoto, T., Shimizu, T., 1991. Cloning by functional expression of PAF receptor from guinea-pig lung. Nature 349, 342-346.
24. Hwang, S.-B., Lam, M.-H., 1986. Species difference in the specific receptors of platelet activating factor. Biochem. Pharmacol. 35, 4511-4518.
25. Hwang, S.B., Lee, C.S., Cheah, M.J., Shen, T.Y., 1983. Specific receptor sites for 1-O-alkyl-2-O-sn-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranes. Biochemistry 22, 4756-4763.
26. Hwang, S.B., Lam, M.H., Shen, T.Y., 1985a. Specific binding sites for platelet-activating factor in human lung tissues. Biochem. Biophys. Res. Commun. 128, 972-979.
27. Hwang, S.B., Li, C.L., Lam, M.H., Shen, T.Y., 1985b. Characterization of cutaneous vascular permeability induced by PAF in guinea pigs and rats and its inhibition by PAF receptor antagonists. Lab. Invest. 52, 617-630.
28. Koltai, M., Hosford, D., Guinot, P., Esanu, A., Braquet, P., 1991. Platelet activating factor. A review of its effects, antagonists and possible future clinical implications. Drugs 42, 9-29, 174-204.
29. Korchak, H.M., Vosshall, L.B., Haines, K.A., Wilkenfeld, C., Lundquist, K.F., Weissmann, G., 1988. Activation of the human neutrophil by calcium-mobilizing ligands. II. Correlation of calcium, diacyl glycerol and phosphatidic acid generation with superoxide anion generation. J. Biol. Chem. 263, 11098-11105.
30. Kuitert, L.M., Hui, K.P., Uthayarkumar, S., Burke, W., Newland, A.C., Uden, S., Barnes, N.C., 1993. Effect of the platelet-activating factor antagonist UK-74,505 on the early and late response to allergen. Am. Rev. Respir. Dis. 147, 82-86.
31. McManus, L.M., Hanahan, D.J., Pinckard, R.N., 1981. Human platelet stimulation by acetyl glyceryl ether phosphorylcholine. J. Clin. Invest. 67, 903-906.
32. Mutoh, H., Bito, H., Minami, M., Nakamura, M., Honda, Z., Izumi, T., Nakata, R., Kurachi, Y., Terano, A., Shimizu, T., 1993. Two different promoters direct expression of two distinct forms of mRNAs of human PAF receptor. FEBS Lett. 322, 129-134.
33. Nakamura, M., Honda, Z., Izumi, T., Sakanaka, C., Mutoh, H., Minami, M., Bito, H., Seyama, Y., Matsumoto, T., Noma, M., Shimizu, T., 1991. Molecular cloning and expression of PAF receptor from human leukocytes. J. Biol. Chem. 266, 20400-20405.
34. Ostermann, G., Till, U., Thielmann, K., 1983. Studies on the stimulation of human blood platelets by semi-synthetic platelet-activating factor. Thromb. Res. 30, 127-136.
35. Prescott, S.M., Zimmerman, G.A., McIntyre, T.M., 1990. Platelet-activating factor. J. Biol. Chem. 265, 17381-17384.
36. Qi, M., Jones, S.B., 1990. Contribution of platelet activating factor to hemodynamic and sympathetic responses to bacterial endotoxin in conscious rats. Circ. Shock 32, 153-163.
37. Qu, X.F., Hayashi, M., Yamaki, K., Oh-Ishi, S.O., 1990. Assessment of vascular permeability increase in the mouse by dye leakage during paw edema. Jpn. J. Pharmacol. 52, 500-503.
38. Rackow, E.C., Astiz, M.E., 1993. Mechanisms and management of septic shock. Crit. Care Clin. 9, 219-237.
39. Sanchez Crespo, M., Fernandez-Gallardo, S., 1991. Pharmacological modulation of PAF: a therapeutic approach to endotoxin shock. J. Lipid Mediat. 4, 127-144.
40. Schild, H.O., 1947. pA, a new scale for the measurement of drug antagonism. Br. J. Pharmacol. 2, 189-195.
41. Shimizu, T., Honda, Z., Nakamura, M., Bito, H., Izumi, T., 1992. PAF receptor and signal transduction. Biochem. Pharmacol. 44, 1001-1008.
42. Snyder, F. (Ed.), 1987. Platelet-Activating Factor and Related Lipid Mediators. Plenum, New York, NY.
43. Summers, J.B., Albert, D.H., 1995. Platelet activating factor antagonists. Adv. Pharmacol. 32, 67-168.
44. Sun, X.M., Hsueh, W., 1991. Platelet-activating factor produces shock, in vivo complement activation, and tissue injury in mice. J. Immunol. 147, 509-514.
45. Tamura, G., Takishima, T., Mue, S., Makino, S., Itoh, K., Miyamoto, T., Shida, T., Nakajima, S., 1994. Effectiveness of a potent platelet activating factor antagonist, WEB-2086, on asthma: a multicenter, double-blind, placebo-controlled study. Eur. Respir. J. 7 (Suppl. 18), 752.
46. Terashita, Z., Imura, Y., Nishikawa, K., Sumida, S., 1985. Is platelet activating factor (PAF) a mediator of endotoxin shock? Eur. J. Pharmacol. 109, 257-261.
47. Terashita, Z., Takatani, M., Nishikawa, K., 1992. Pharmacological profile of TCV-309 - a potent PAF antagonist. J. Lipid Mediat. 5, 183-185.
48. Torley, L.W., Pickett, W.C., Carroll, M.L., Kohler, C.A., Schaub, R.E., Wissner, A., DeJoy, S.Q., Oronsky, A.L., Kerwar, S.S., 1992. Studies of the effect of a platelet-activating factor antagonist, CL 184,005, in animal models of gram-negative bacterial sepsis. Antimicrob. Agents Chemother. 36, 1971-1977.
49. Wallace, J.L., Steel, G., Whittle, B.J., Lagente, V., Vargaftig, B., 1987. Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat. Effects of three platelet-activating factor antagonists. Gastroenterology 93, 765-773.
50. Wilkens, J.H., Wilkens, H., Uffmann, J., Bovers, J., Fabel, H., Frolich, J.C., 1990. Effects of a PAF antagonist (BN-52063) on bronchoconstriction and platelet activation during exercise induced asthma. Br. J. Clin. Pharmacol. 29, 85-91.